Narrative review describes necroptosis-senescence pathway in kidney fibrosis with preclinical but untranslated senolytic evidence.
This narrative review synthesized peer-reviewed literature on necroptosis, cellular senescence, and renal tubulointerstitial fibrosis, searching PubMed, Web of Science, and Embase through July 2026. The authors describe a proposed mechanistic continuum where mitochondrial DNA released from necroptotic tubular cells drives glycolytic reprogramming and a senescence-associated secretory phenotype that amplifies fibrosis. Senolytics are mentioned among existing targeted strategies showing "preclinical efficacy" but the review does not report actual senolytic trial data, effect sizes, or clinical translation success.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Sep 3, 2026 · Discovered: Sep 18, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Systematic review
- Sample size
- —
- Duration
- —
- Population
- Renal tubular epithelial cells and interstitial fibroblasts in the context of chronic kidney disease progressing to tubulointerstitial fibrosis
- Primary outcome
- Mechanistic characterization of the mtDNA-cGAS-STING-PFKFB3 axis in necroptosis-senescence crosstalk during tubulointerstitial fibrosis
- Effect size
- —
- Significance
- Not reported
- Journal
- Frontiers in Medicine
- Published
- Sep 3, 2026
Sources
Primary source
- Frontiers in medicine ↗Peer reviewed
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.